OBJECTIVETo describe a new FOXL2 gene mutation in a woman with sporadic blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) and hypergonadotropic hypogonadism.DESIGNCase report.SETTINGUniversity medical center.PATIENT(S)A 28-year-old woman.INTERVENTION(S)Clinical evaluation, hormone assays, gene mutation research.MAIN OUTCOME MEASURE(S)FOXL2 gene mutation.RESULT(S)The patient with hypergonadotropic hypogonadism was diagnosed with BPES due to a new FOXL2 gene mutation.CONCLUSION(S)Blepharophimosis-ptosis-epicanthus inversus syndrome is a rare disorder associated with premature ovarian failure (POF). The syndrome is an autosomal dominant trait that causes eyelid malformations and POF in affected women. Mutations in FOXL2 gene, located in chromosome 3, are related to the development of BPES with POF (BPES type I) or without POF (BPES type II). This report demonstrates a previously undescribed de novo mutation in the FOXL2 gene-a thymidine deletion, c.627delT (g.864delT)-in a woman with a sporadic case of BPES and POF. This mutation leads to truncated protein production that is related to a BPES type I phenotype. This report shows the importance of family history and genetic analysis in the evaluation of patients with POF and corroborates the relationship between mutations on the FOXL2 gene and ovarian insufficiency.